HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces the publication of a landmark study in the Journal of Affective Disorders demonstrating the potential efficacy of its proprietary DIFS technology. The research highlights the potential of DIFS to deliver meaningful reductions in systolic and diastolic blood pressure in patients with major depressive dis ...

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces the publication of a landmark study in the Journal of Affective Disorders demonstrating the potential efficacy of its proprietary DIFS technology. The research highlights the potential of DIFS to deliver meaningful reductions in systolic and diastolic blood pressure in patients with major depressive dis ...

HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar today, January 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Ne ...

DIFS Technology: A Potential Game-Changer for Mental Health Treatments Setting New Benchmarks: 65% Response Rate Shown in Completed Depression Trials Alzheimer’s Research Shows Promising Results with Increased Brain Activity Virtual Clinic Poised to Revolutionize Mental Health Care with AI Integration Pursuing CE Mark to Expand into European Markets in 2025 Strategic Focus on PTSD, TBI, and Addiction Research for Veterans Global Growth with Approvals in China, Brazil, and Oman Neuromodulation Market Positi ...

AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2HOUSTON, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, is pleased to announce the launch of Phase 1 of its proprietary virtual clinic. The virtual clinic will utilize artificial intelligence (AI) and Nexalin’s new Electronic Data Capture (EDC) platform and Patient Monitoring ...

HOUSTON, TX, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) announces that its proprietary Deep Intracranial Frequency Stimulation (DIFS) technology is prominently featured in a newly published editorial in Psychotherapy and Psychosomatics. This peer-reviewed article provides compelling validation of Nexalin’s ability to non-invasively treat challenging psychiatric conditions, highlighting the Company’s unique positioning in the rapidly growing n ...

HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexal ...

Core Viewpoint - Nexalin Technology, Inc. has published a significant study demonstrating the effectiveness of its Deep Intracranial Frequency Stimulation (DIFS) technology in enhancing brain function and cognitive performance in patients with mild Alzheimer's disease, as reported in the Journal of Alzheimer's Disease [1][5]. Study Overview - The study involved 46 patients who were randomly assigned to receive either real DIFS or sham treatment over 30 one-hour sessions within three weeks, utilizing resting-state functional magnetic resonance imaging (rs-fMRI) to monitor brain activity changes [2]. Key Findings - **Increased Neuronal Activity and Glucose Metabolism**: Real DIFS treatment led to significant increases in fractional amplitude of low-frequency fluctuation (fALFF) in the prefrontal cortex, correlating with improved glucose metabolism, which is vital for cognitive function [3]. - **Sustained Cognitive Benefits**: Improvements in cognitive function were observed three months post-treatment, with increased neuronal activity in memory-related brain regions, indicating long-lasting effects of DIFS [3]. - **Enhanced Brain Connectivity**: The study showed improved regional homogeneity (ReHo) in specific frontal gyrus areas, suggesting better synchronization of neural activity and enhanced communication pathways in the brain [3]. - **Correlations with Improved Blood Flow and Brain Function**: Enhanced blood flow in critical regions was noted, correlating with increased neuronal activity and suggesting DIFS's potential to restore disrupted metabolic processes in Alzheimer's patients [3]. - **Safe and Well-Tolerated Treatment**: No serious side effects were reported, with only minor sensations experienced by participants, highlighting the treatment's safety profile for vulnerable populations [3]. Industry Context - With over 50 million people affected by Alzheimer's disease globally, projected to rise to over 113 million by 2050, there is a pressing need for innovative therapies that address cognitive decline's root causes [4]. - Current treatments mainly focus on symptom management, while Nexalin's DIFS technology aims to modulate brain activity and restore metabolic functions, presenting a new treatment avenue for Alzheimer's [4]. Company Insights - Nexalin's DIFS technology has shown significant improvements in cognitive function, as evidenced by gains in Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores, reinforcing the potential of non-invasive stimulation therapies in Alzheimer's treatment [5]. - The Chief Medical Officer of Nexalin expressed optimism regarding DIFS's ability to improve cognitive function in a well-tolerated manner, addressing underlying causes of cognitive decline [6]. - The CEO of Nexalin highlighted the study as a milestone for DIFS technology, emphasizing its potential to restore brain function and improve cognitive performance in Alzheimer's patients [6].

Core Insights - Nexalin Technology, Inc. is initiating a new clinical trial for its Gen-3 Halo headset in collaboration with the University of California, San Diego, focusing on treating veterans with mild Traumatic Brain Injury (mTBI) through a virtual clinic model [1][2][5] - The Gen-3 Halo headset utilizes Nexalin's proprietary Deep Intracranial Frequency Stimulation (DIFS®) technology, featuring an advanced 15 milliamp waveform, aimed at enhancing convenience for in-home treatment while maintaining clinical precision [2][6] - The study aligns with the Veterans Administration's goal of expanding telehealth services for veterans, with over $17 billion allocated for mental health services in their 2025 Professional Judgement Budget [3] Study Design and Objectives - The trial will assess the effectiveness of the Gen-3 Halo headset by interpreting MEG signals and measuring changes in brain activity and symptom relief in veterans with mTBI [4][5] - Two participant groups will be recruited: Group 1 will receive treatment with the Gen-3 Halo headset, while Group 2 will be assigned a sham device for comparison [4] Enhanced Access to Care - The Gen-3 Halo headset represents a significant advancement in neuromodulation technology, designed for at-home use within a virtual clinic model, enhancing patient convenience and ensuring targeted treatment [6] - Previous trials using the Gen-2 console device showed notable improvements in brain activity and pain reduction among participants, laying the groundwork for the current study [6][7] Company Overview - Nexalin Technology designs and develops innovative neurostimulation products aimed at addressing the global mental health epidemic, with a focus on non-invasive treatments [7]

Core Viewpoint - Nexalin Technology, Inc. has announced positive results from a clinical trial using its Deep Intracranial Frequency Stimulation (DIFS) technology, showing improvements in memory and cognitive function for patients with mild Alzheimer's disease [1][4]. Group 1: Clinical Trial Results - The clinical trial enrolled 46 patients, with 23 receiving DIFS treatment, resulting in significant improvements in cognitive markers, including Mini-Mental State Examination (MMSE) scores (p = 0.041) and Montreal Cognitive Assessment (MoCA) scores (p = 0.025) [2][3]. - Functional MRI (fMRI) scans indicated increased local neural activity and blood flow in the hippocampus, a critical area for memory processing, suggesting that DIFS may positively influence brain function [2][3]. Group 2: Treatment Efficacy and Tolerability - The DIFS group exhibited statistically significant improvement in memory, as measured by the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), compared to the sham group [3]. - The treatment was well-tolerated, with only minor side effects such as mild tingling during stimulation sessions, which resolved quickly [3]. Group 3: Company Insights and Future Plans - Dr. David Owens, Chief Medical Officer, emphasized the milestone nature of the study and the potential of non-invasive brain stimulation to transform Alzheimer's treatment [4]. - The CEO, Mark White, highlighted the promise of DIFS as a drug-free alternative or in combination with existing treatments, and mentioned plans for a robust clinical trial utilizing different waveform frequencies to enhance clinical response [4]. Group 4: Company Background - Nexalin Technology, Inc. designs and develops innovative neurostimulation products aimed at addressing mental health issues, utilizing bioelectronic medical technology [5]. - The Nexalin Gen-2 15 milliamp neurostimulation device has received approval in China, Brazil, and Oman, indicating the company's commitment to advancing its technology [5].